Abstract
Acute leukemias are clonal disorders of hematopoiesis wherein a leukemic stem cell (LSC) acquires mutations that confer the capacity for unlimited self-renewal, impaired hematopoietic differentiation, and enhanced proliferation to the leukemic clone. Many recent advances in understanding the biology of leukemia have come from studies defining specific genetic and epigenetic abnormalities in leukemic cells. Three recent articles, however, further our understanding of leukemia biology by elucidating specific abnormalities in metabolic pathways in leukemic hematopoiesis. These studies potentially converge on the concept that modulation of reactive oxygen species (ROS) abundance may influence the pathogenesis and treatment of acute myeloid leukemia (AML).
Publication types
-
Research Support, Non-U.S. Gov't
-
Comment
MeSH terms
-
Animals
-
Cholecalciferol / pharmacology
-
Cholecalciferol / therapeutic use
-
Glutarates / metabolism
-
Hematopoiesis / drug effects
-
Hematopoiesis / physiology*
-
Hematopoietic Stem Cells / cytology
-
Hematopoietic Stem Cells / metabolism
-
Humans
-
Hypoxia-Inducible Factor 1, alpha Subunit / metabolism
-
Iron Chelating Agents / pharmacology
-
Iron Chelating Agents / therapeutic use
-
Isocitrate Dehydrogenase / genetics
-
JNK Mitogen-Activated Protein Kinases / metabolism
-
Leukemia / drug therapy
-
Leukemia / genetics
-
Leukemia / metabolism*
-
Leukemia / pathology*
-
Leukemia, Myeloid, Acute / drug therapy
-
Leukemia, Myeloid, Acute / genetics
-
Leukemia, Myeloid, Acute / metabolism
-
Models, Biological
-
Mutation, Missense / genetics
-
NADP / metabolism
-
Neoplastic Stem Cells / cytology
-
Neoplastic Stem Cells / metabolism*
-
Reactive Oxygen Species / metabolism*
Substances
-
Glutarates
-
Hypoxia-Inducible Factor 1, alpha Subunit
-
Iron Chelating Agents
-
Reactive Oxygen Species
-
Cholecalciferol
-
alpha-hydroxyglutarate
-
NADP
-
IDH2 protein, human
-
Isocitrate Dehydrogenase
-
IDH1 protein, human
-
JNK Mitogen-Activated Protein Kinases